GlassScriptPhysician profile
Kyle Aaron Bray
NPI 1144740234
$6,741.35
in general payments reported to CMS, 2019-2025
33 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,516 · 2020: $1,105 · 2021: $483 · 2022: $595 · 2023: $654 · 2024: $797 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869 · Travel and Lodging: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.53 |
| Travel and Lodging | $174.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,521.57 | 2019-2025 | Prophecy, Limflow System, Prostep |
| Rock Medical Orthopedics, INC. | $1,072.78 | 2019 | |
| Medical Device Business Services, INC. | $491.97 | 2019-2020 | |
| Integra Lifesciences Corporation | $390.18 | 2019-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Organogenesis INC. | $364.40 | 2020-2025 | Puraply, Cygnus Dual |
| Smith+Nephew, INC. | $312.22 | 2019-2024 | Stravix, Grafix |
| Aroa Biosurgery Incorporated | $183.31 | 2024 | |
| Treace Medical Concepts, INC. | $155.73 | 2022-2025 | |
| Horizon Therapeutics Plc | $151.55 | 2019-2023 | Krystexxa |
| Abbott Laboratories | $139.97 | 2024 | Jeti All In One Non-Sterile Kit |
| Wright Medical Technology, INC. | $114.47 | 2019 | |
| Zimmer Biomet Holdings, INC. | $108.72 | 2021 | |
| Arteriocyte Medical Systems, INC. | $106.67 | 2021-2025 | Magellan |
| Paragon 28, INC. | $88.57 | 2024 | Precision Mis Bunion, Mtp |
| Kerecis Limited | $78.37 | 2021-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $70.08 | 2024-2025 | Krystexxa |
| Nabriva Therapeutics, Plc | $58.98 | 2021-2022 | |
| Orthofix Medical, INC. | $54.79 | 2022 | |
| Kci USA, INC. | $38.97 | 2019-2023 | V.A.C. Veraflo, V.A.C. Dermatac, Activ.A.C. |
| Paratek Pharmaceuticals, INC. | $24.51 | 2020-2021 | |
| Depuy Synthes Sales INC. | $21.23 | 2025 | Na |
| Bard Peripheral Vascular, INC. | $18.75 | 2019 | |
| Bioventus LLC | $18.48 | 2020 | |
| Medtronic, INC. | $17.77 | 2023 | Hawkone |
| Axogen | $17.50 | 2025 | |
| Nevro Corp. | $17.44 | 2023 | Senza |
| Mimedx Group, INC. | $17.43 | 2024 | |
| Triad Life Sciences INC. | $16.64 | 2022 | |
| Cashflow Solutions, LLC | $16.50 | 2023 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
| Ani Pharmaceuticals, INC. | $15.40 | 2024 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $13.40 | 2019 | |
| Melinta Therapeutics, LLC | $11.77 | 2019 | |
| Acell, INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Bray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.